Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain

Immunopharmacol Immunotoxicol. 2000 Aug;22(3):451-64. doi: 10.3109/08923970009026005.

Abstract

Three pups 2-4 months old were vaccinated subcutaneously with the modified live canine parvovirus, CPV-2b/29-97 strain. During an observation period of two weeks pups remained clinically health, exhibiting a vigorous post-vaccinal active serological response (haemoagglutinating inhibiting antibody titers for CPV-2 ranging from 1:2560 to 1:5120 at 21 days post inoculation). Phagocytosis and killing of Candida albicans exerted by polymorphonuclear cells and monocytes did not undergo significant modifications 3-6 days post vaccination up to 30 days. Antibacterial activity mediated by peripheral blood lymphocytes (Salmonella typhi was used as a target) was slightly, but not significantly decreased 3 days post vaccination. Conclusively, in pups the CPV type 2b vaccine seems to be safe as far as natural immune responses are concerned, while its immunogenicity is preserved.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral / blood
  • Blood Bactericidal Activity
  • Candida albicans / immunology
  • Dog Diseases / immunology
  • Dog Diseases / prevention & control
  • Dogs
  • Immunity, Innate*
  • In Vitro Techniques
  • Injections, Subcutaneous
  • Monocytes / immunology
  • Neutrophils / immunology
  • Parvoviridae Infections / immunology
  • Parvoviridae Infections / prevention & control
  • Parvoviridae Infections / veterinary
  • Parvovirus, Canine / classification
  • Parvovirus, Canine / immunology*
  • Phagocytosis
  • Safety
  • Salmonella typhi / immunology
  • Viral Vaccines / administration & dosage*
  • Viral Vaccines / adverse effects

Substances

  • Antibodies, Viral
  • Viral Vaccines